Onsite rapid testing begins

All attendees, speakers, and staff will be asked to complete a Covid-19 rapid antigen test upon arrival. Please allow at least 20 minutes to complete this process before proceeding to the event space.

Networking breakfast begins

Buffet breakfast will be served with ample space for attendee networking.

Welcome from STAT

Patient spotlight

Welcome Remarks

Bristol Myers Squibb: Big steps

2022 is set to be a big year for BMS, with a new heart drug, a treatment for psoriasis, and, perhaps most importantly, the third new type of medicine in a category BMS pioneered: immune therapies to fight cancer by allowing the immune system to attack it. The CEO speaks.

The Paxlovid story

These scientists developed an effective oral drug to treat Covid-19 in less than two years. Hear how it happened firsthand.

Interstitial

Investigating new molecular pathways to unlock breakthrough treatments

Forging into under-explored avenues of scientific research could help patients with rare, autoimmune, and inflammatory disorders.

Patient spotlight

CRISPR at a crossroads

Last summer, long before most people would have expected it, researchers accomplished a first: the editing of genes inside living people in order to treat disease. A look at what happens next.

Patient spotlight

Coffee Break

Sponsored by Ocugen

Are incarcerated people being denied one of medicine’s biggest breakthroughs?

Hepatitis C, the liver-destroying virus, is epidemic in prisons. New oral drugs have revolutionized its treatment. Incarcerated people don’t always get them.

Searching for new ways to address inflammatory disease

Inflammatory diseases like psoriasis, rheumatoid arthritis, and asthma afflict an increasing number of people. Here’s how we can better understand the biology behind these illnesses in order to develop new medicines.

STAT Madness

Each year, universities, and research institutions across the country compete in STAT’s bracket-style tournament, STAT Madness, to be crowned the top innovation or discovery of the year. This year, for the first time, three finalists will take the stage to present their work to our panel of expert judges. Then, one will be selected as our STAT Summit pick by event attendees.

Lunch

The new FDA commissioner speaks

Robert Califf has done the job before. But now he has his work cut out for him. Are drug approvals too fast or too slow? Has the agency changed its standards? How will it regulate tobacco and opioids? Come hear his thoughts firsthand.

Patient spotlight

Health equity means research equity

Medical breakthroughs and advances in precision medicine are driven by scientific data and translational knowledge of disease(s) that impact an individual or a population. A discussion of why ensuring inclusivity at the earliest phases of research and throughout the R&D process is critical to reduce disparities in healthcare.

Pig-to-human transplants?

This year, doctors crossed a Rubicon: pig organs have been transplanted into human beings. Given the number of people who die due to lack of kidneys, hearts, and other organs, the potential of such work is huge. A look at the scientific and ethical hurdles ahead.

Interstitial

Merck: What’s next for its research labs?

Over the past decade, Merck has delivered for patients and investors because of one drug: the cancer medicine Keytruda. Now, new R&D head Dean Li lays out what’s next after some big wins and also some setbacks.

Coffee Break

Sponsored by Ocugen.

Biotech’s event horizon

When an idea for a new medicine emerges in academia, it’s time to form a company around it. But the negotiations between venture capitalists and the offices that guard intellectual property at universities can be fraught — and many good ideas never escape their gravity. A look at one of the great barriers to innovation.

Transforming breakthrough science into real treatments

Increasingly complex pipelines across multiple modalities are transforming biopharmaceutical ecosystems. New expertise and scalable manufacturing platforms are required to turn promising molecules into effective treatments. How will this evolve and what does the industry need to do now to adapt?

Interstitial

Inside a billionaire’s plan to lower drug costs

The noted entrepreneur, investor, and Shark Tank-er Mark Cuban has long been clearly infuriated by the strange economics of the drug industry. Now he’s backing an effort to make many medicines far cheaper. STAT’s Pharmalot will go deep with the company’s CEO to explain what it is doing and what it may accomplish.

The scientist as entrepreneur

The Covid pandemic gave Regeneron a chance to show what it could do, as its monoclonal antibody made the company famous outside the biotech industry. Now one of biotech’s most outspoken executives lays out the plans that he says will keep the company ahead of the curve.

Rethinking health in the digital age

New technologies could shift the focus of medicine from late-stage disease management to early detection and disease prevention. Here’s how digital health advancements are changing the way doctors and patients work together to solve problems in asthma, diabetes, and other diseases.

Covid: From NYC 2020 to now

The outbreak in New York City at the pandemic’s beginning was the worst America has seen. A look at what we have learned since then and what we can expect next.

Aduhelm and equity

Should Medicare pay for the controversial Alzheimer’s drug outside of clinical trials? One side says no, in part because those trials included very few people of color. Another says yes, because restricting the drug means disadvantaged people won’t get a chance to receive it. A discussion between proponents of both perspectives.

Closing Remarks

Closing from STAT

Networking reception begins